Guggenheim Capital’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $666K | Buy |
38,453
+3,105
| +9% | +$53.7K | 0.01% | 1042 |
|
|
2025
Q1 | $773K | Buy |
35,348
+2,741
| +8% | +$59.9K | 0.01% | 990 |
|
|
2024
Q4 | $1.04M | Sell |
32,607
-5,322
| -14% | -$170K | 0.01% | 898 |
|
|
2024
Q3 | $1.09M | Buy |
37,929
+4,316
| +13% | +$124K | 0.01% | 1049 |
|
|
2024
Q2 | $1.29M | Buy |
33,613
+111
| +0.3% | +$4.26K | 0.01% | 989 |
|
|
2024
Q1 | $1.97M | Buy |
33,502
+1,932
| +6% | +$114K | 0.01% | 884 |
|
|
2023
Q4 | $1.89M | Sell |
31,570
-9,535
| -23% | -$571K | 0.01% | 866 |
|
|
2023
Q3 | $1.56M | Buy |
41,105
+9,645
| +31% | +$367K | 0.01% | 896 |
|
|
2023
Q2 | $2.87M | Sell |
31,460
-4,532
| -13% | -$413K | 0.02% | 715 |
|
|
2023
Q1 | $2.37M | Sell |
35,992
-12,815
| -26% | -$845K | 0.02% | 785 |
|
|
2022
Q4 | $2.52M | Buy |
48,807
+13,288
| +37% | +$687K | 0.02% | 769 |
|
|
2022
Q3 | $2.43M | Sell |
35,519
-6,159
| -15% | -$421K | 0.02% | 764 |
|
|
2022
Q2 | $1.88M | Sell |
41,678
-1,421
| -3% | -$64.2K | 0.01% | 911 |
|
|
2022
Q1 | $2.19M | Sell |
43,099
-5,152
| -11% | -$262K | 0.01% | 960 |
|
|
2021
Q4 | $2.28M | Buy |
48,251
+4,607
| +11% | +$218K | 0.01% | 990 |
|
|
2021
Q3 | $1.44M | Buy |
+43,644
| New | +$1.44M | 0.01% | 1222 |
|